Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Dow
Baxter
Johnson and Johnson
Moodys
Medtronic

Last Updated: January 26, 2023

Details for Patent: 8,969,355


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Summary for Patent: 8,969,355
Title:1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1a activity for the treatment of cognitive impairment
Abstract: This disclosure relates to a method of treating a disease selected from the group consisting of affective disorders, depression, major depressive disorder, anxiety, general anxiety disorder, social anxiety disorder, obsessive compulsive disorder, panic disorder, and panic attacks. The method includes administering a therapeutically effective amount of Compound I or a pharmaceutically acceptable salt thereof to a patient in need thereof, in which Compound I is 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine.
Inventor(s): Bang-Andersen; Benny (Copenhagen S, DK), Faldt; Andre (Ishoj, DK), Holm; Rene (Jyllinge, DK), de Diego; Heidi Lopez (Naerum, DK)
Assignee: H. Lundbeck A/S (Valby, DK)
Application Number:14/480,949
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,969,355
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 8,969,355

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Takeda Pharms Usa TRINTELLIX vortioxetine hydrobromide TABLET;ORAL 204447-001 Sep 30, 2013 RX Yes No See Plans and Pricing See Plans and Pricing METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER See Plans and Pricing
Takeda Pharms Usa TRINTELLIX vortioxetine hydrobromide TABLET;ORAL 204447-002 Sep 30, 2013 RX Yes No See Plans and Pricing See Plans and Pricing METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER See Plans and Pricing
Takeda Pharms Usa TRINTELLIX vortioxetine hydrobromide TABLET;ORAL 204447-003 Sep 30, 2013 DISCN Yes No See Plans and Pricing See Plans and Pricing METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER See Plans and Pricing
Takeda Pharms Usa TRINTELLIX vortioxetine hydrobromide TABLET;ORAL 204447-004 Sep 30, 2013 RX Yes Yes See Plans and Pricing See Plans and Pricing METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,969,355

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Denmark2006 00824Jun 16, 2006
Denmark2006 01223Sep 22, 2006
Denmark2006 01384Oct 25, 2006
Denmark2007 00427Mar 20, 2007

International Family Members for US Patent 8,969,355

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 061481 See Plans and Pricing
Argentina 065797 See Plans and Pricing
Austria 495745 See Plans and Pricing
Austria 540941 See Plans and Pricing
Australia 2007260355 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Medtronic
Moodys
Baxter
Merck
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.